Abstract:Background: Chronic obstructive pulmonary disease (COPD) is a common disease characterized by progressive airflow obstruction, influenced by genetic and environmental factors. Eosinophils have been implicated in COPD pathogenesis, prompting the categorization into eosinophilic and non-eosinophilic endotypes. This study explores the association between eosinophilic inflammation and mRNA expression of ELAVL1, ZfP36, and HNRNPD genes, which encode HuR, TTP and AUF-1 proteins, respectively. Additionally, it investigates the expression of IL-9 and IL-33 in COPD patients with distinct eosinophilic profiles. Understanding these molecular associations could offer insights into COPD heterogeneity and provide potential therapeutic targets. Methods: We investigated 50 COPD patients, of whom 21 had eosinophilic inflammation and 29 had non-eosinophilic inflammation. Epidemiological data, comorbidities, and pulmonary function tests were recorded. Peripheral blood mononuclear cells were isolated for mRNA analysis of ELAVL1, ZfP36, and HNRNPD genes and serum cytokines (IL-9, IL-33) were measured using ELISA kits. Results: The study comprised 50 participants, with 66% being male and a mean age of 68 years (SD: 8.9 years). Analysis of ELAVL1 gene expression revealed a 0.45-fold increase in non-eosinophilic and a 3.93-fold increase in eosinophilic inflammation (p = 0.11). For the ZfP36 gene, expression was 6.19-fold higher in non-eosinophilic and 119.4-fold higher in eosinophilic groups (p = 0.07). Similarly, HNRNPD gene expression was 0.23-fold higher in non-eosinophilic and 0.72-fold higher in eosinophilic inflammation (p = 0.06). Furthermore, serum levels of IL-9 showed no statistically significant difference between the eosinophilic and non-eosinophilic group (58.03 pg/mL vs. 52.55 pg/mL, p = 0.98). Additionally, there was no significant difference in IL-33 serum levels between COPD patients with eosinophilic inflammation and those with non-eosinophilic inflammation (39.61 pg/mL vs. 37.94 pg/mL, p = 0.72). Conclusions: The data suggest a notable trend, lacking statistical significance, towards higher mRNA expression for the ZfP36 and HNRNPD genes for COPD patients with eosinophilic inflammation compared to those with non-eosinophilic inflammation.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the relationship between eosinophilic inflammation in chronic obstructive pulmonary disease (COPD) and the mRNA gene expressions of ELAVL1, ZfP36 and HNRNPD, which encode HuR, TTP and AUF - 1 proteins respectively. In addition, the study also aims to investigate whether there are differences in the expressions of IL - 9 and IL - 33 cytokines in different eosinophilic phenotypes in COPD patients. Through these studies, the authors hope to understand these molecular associations, thereby providing insights into the heterogeneity of COPD and potentially discovering potential therapeutic targets. ### Research Background COPD is a common disease, characterized by progressive airflow limitation, and is influenced by genetic and environmental factors. Eosinophils play an important role in the pathogenesis of COPD, prompting COPD to be divided into eosinophilic and non - eosinophilic types. HuR, TTP and AUF - 1 are three important RNA - binding proteins, which play a key role in regulating RNA metabolic processes, including RNA production, cellular localization and transport, stability and translation, etc. Abnormal expressions of these proteins may be related to the pathological process of COPD. ### Research Methods The study included 50 COPD patients, among whom 21 had eosinophilic inflammation and 29 did not. The researchers recorded epidemiological data, comorbidities and lung function test results, and isolated mRNA from peripheral blood mononuclear cells to analyze the expressions of ELAVL1, ZfP36 and HNRNPD genes. Meanwhile, ELISA kits were used to measure the levels of IL - 9 and IL - 33 in serum. ### Main Results - **ELAVL1 gene**: In the non - eosinophilic inflammation group, the mRNA expression of the ELAVL1 gene was 0.45 times higher than that of β2 - microglobulin; in the eosinophilic inflammation group, the mRNA expression of the ELAVL1 gene was 3.93 times higher than that of β2 - microglobulin (p = 0.11). - **ZfP36 gene**: In the non - eosinophilic inflammation group, the mRNA expression of the ZfP36 gene was 6.19 times higher than that of β2 - microglobulin; in the eosinophilic inflammation group, the mRNA expression of the ZfP36 gene was 119.4 times higher than that of β2 - microglobulin (p = 0.07). - **HNRNPD gene**: In the non - eosinophilic inflammation group, the mRNA expression of the HNRNPD gene was 0.23 times higher than that of β2 - microglobulin; in the eosinophilic inflammation group, the mRNA expression of the HNRNPD gene was 0.72 times higher than that of β2 - microglobulin (p = 0.06). - **IL - 9 and IL - 33 cytokines**: There were no significant differences in the levels of IL - 9 and IL - 33 in serum between the eosinophilic inflammation group and the non - eosinophilic inflammation group. ### Discussion Although the research results show that there are trends in the mRNA expressions of ELAVL1, ZfP36 and HNRNPD genes between the eosinophilic inflammation group and the non - eosinophilic inflammation group, these differences did not reach statistical significance. This may mean that these genes do have different expression patterns in different subtypes of COPD, but a larger sample size or more precise experimental design is required for further verification. In addition, the study also emphasizes the importance of RNA - binding proteins in the pathological process of COPD, especially their role in regulating the inflammatory response. Future research can further explore the possibility of these proteins as potential therapeutic targets.

Endotyping Eosinophilic Inflammation in COPD with ELAVL1, ZfP36 and HNRNPD mRNA Genes

Eosinophils Promote Pulmonary Matrix Destruction and Emphysema Via Cathepsin L

Identification of Genes Related to Endoplasmic Reticulum Stress (ERS) in Chronic Obstructive Pulmonary Disease (COPD) and Clinical Validation

The Heterogeneity of Inflammatory Response and Emphysema in Chronic Obstructive Pulmonary Disease

Transcriptional profiles of peripheral eosinophils in chronic obstructive pulmonary disease and asthma—An exploratory study

Eosinophilic inflammation: a key player in COPD pathogenesis and progression

Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes

Inflammatory Endotype-Associated Airway Resistome in Chronic Obstructive Pulmonary Disease

Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study

Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD

Inflammatory endotypes in COPD

Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue

Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait

Clinical differences between eosinophilic and non-eosinophilic acute exacerbation of chronic obstructive pulmonary disease (AECOPD), a multicenter cross-sectional study

Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations

Eosinopenia and ILC2 Immune Dysfunction in COPD Exacerbation is Associated to the Upregulation of ILC3/IL-22 Axis

The association between blood eosinophils and clinical outcome of acute exacerbations of chronic obstructive pulmonary disease: A systematic review and meta-analysis

Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients

Blood eosinophils in COPD: friend or foe?

Identification of novel biomarkers related to neutrophilic inflammation in COPD

Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype